Top Story

Omalizumab linked to improved disease activity in SLE

Omalizumab linked to improved disease activity in SLE
January 16, 2019

Supporting early career scientists aims to avert lost generation of lupus researchers

January 4, 2019
With the need for rheumatologists expected to outpace national demand by 2030, the necessity to get more physicians into the field becomes more pronounced with each…
In the JournalsPerspective

SLE linked to increased risk for 16 cancers, decreased risk for melanoma

January 2, 2019
Systemic lupus erythematosus is associated with an increased risk for 16 cancers, including Hodgkin’s and non-Hodgkin’s lymphoma, leukemia and multiple…
FDA News

FDA grants fast track status to baricitinib development for SLE

December 13, 2018
The FDA granted fast track designation to baricitinib for the treatment of systemic lupus erythematosus, according to the drug’s manufacturer. Following phase 2…
More Headlines »

Highlights of the Rheumatology Summit: A Master Class in RA, PsA, and SpA

This activity is supported by independent educational grants from AbbVie; Celgene Corporation; Lilly USA, LLC; Merck & Co., Inc.; and Pfizer, Inc.

This CME-certified monograph is specifically designed for health care professionals to advance their knowledge…
More »
Meeting News

VIDEO: Interferon-induced APOL1 over-expression linked to autophagic dysfunction

December 1, 2017
More »

Updates in PsA and SpA: Optimizing Care Among the Latest Advances

This activity is supported by an educational grant from Lilly.

Chronic inflammatory diseases, such as psoriatic arthritis (PsA) and ankylosing spondylitis (AS), represent a group of…
More »